VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients

Ozgon, G.; Langaee, T.; feng, h; Buyru, AYŞE; Ulutin, ALİ; Hatemi, A.; Siva, AKSEL; Saip, SABAHATTİN; Johnson, J.

doi:10.1007/s00228-008-0507-5

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients

Ozgon G. O., Langaee T. Y., feng h., Buyru N., Ulutin T., Hatemi A. C., ...Daha Fazla

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, cilt.64, sa.9, ss.889-894, 2008 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 64 Sayı: 9
Basım Tarihi: 2008
Doi Numarası: 10.1007/s00228-008-0507-5
Dergi Adı: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.889-894
Anahtar Kelimeler: warfarin, dose, polymorphism, genotype, pharmacogenetics, REDUCTASE COMPLEX SUBUNIT-1, COAGULATION-FACTOR, AFRICAN-AMERICANS, PHARMACOGENETICS, GENOTYPE, GENE, RESISTANCE
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Objectives The objective of this study was to determine the quantitative influence of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP 2C9) polymorphisms on warfarin dose requirements in Turkish patients.